{"id":"W2135484010","doi":"10.1016/s0140-6736(13)60023-9","title":"Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials","year":2013,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes and associated disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":354,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hospital for Sick Children; SickKids Foundation; University of Toronto","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Center for Advancing Translational Sciences; National Institute of Allergy and Infectious Diseases; National Center for Research Resources; U.S. National Library of Medicine; Sanofi; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Child Health and Human Development; Genentech; Dexcom; National Institutes of Health; MacroGenics; Novo Nordisk; Pfizer; Biogen; Juvenile Diabetes Research Foundation United States of America; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Amylin Pharmaceuticals; Amgen; Osiris Therapeutics; Halozyme; American Diabetes Association","keywords":"Medicine; Anakinra; Canakinumab; Type 2 diabetes; Immunology; Diabetes mellitus; Interleukin; Clinical trial; Placebo; Internal medicine; Cytokine; Endocrinology; Disease; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001583941,0.0001588321,0.0009628424,0.00003993473,0.00003282516,0.00003913908,0.000309454,0.00009517542,0.0002017842],"category_scores_gemma":[0.0007786638,0.00009711098,0.000180704,0.0001074373,0.00006094478,0.000005038019,0.00007137494,0.0001120373,0.00003161165],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001269303,"about_ca_system_score_gemma":0.00004690909,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008487354,"about_ca_topic_score_gemma":0.00007631357,"domain_scores_codex":[0.9984182,0.000406806,0.0005277514,0.0001933356,0.0001092563,0.0003447257],"domain_scores_gemma":[0.9989391,0.0002550935,0.0003119391,0.0003535303,0.00009832755,0.00004202919],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2836299,0.0007054927,0.02857332,0.00007893664,0.002130843,0.000001728173,0.0005700998,0.0005418969,0.6289071,0.0001322608,0.03260127,0.02212715],"study_design_scores_gemma":[0.7804731,0.000260939,0.001277181,0.00006218642,0.0001983678,4.28025e-7,0.0003612491,0.0004907706,0.2044668,0.0004423321,0.01162159,0.0003450673],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925125,0.002019971,0.000003707089,0.001374552,0.0002729092,0.001449152,0.00002206111,0.000009359366,0.00233574],"genre_scores_gemma":[0.9967201,0.001867028,0.00005335665,0.0005539514,0.000256606,0.0001740604,0.00009885096,0.00001677881,0.0002592078],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4968432,"threshold_uncertainty_score":0.3960071,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03385455875871329,"score_gpt":0.303971801463244,"score_spread":0.2701172427045307,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}